The result indicated that the ratio of NEUROD1 to ASCL1 may act as a predictive biomarker for the efficacy of SVV-001.228 Kellish et al. studied a modified oncolytic myxoma virus (MYXV) with ability to infect and replicate in tumor cells.229,230 The study demonstrated the safety of intrapulmonary MYXV in an immunocompetent mouse model with SCLC and the viral replication and cytotoxicity in specific tumor cells. The gene discussed is ASCL1; the disease is small cell lung carcinoma.